Connecticut cannabis tax revenue jumps 67% despite flat sales

Tax Revenue Surged While Sales Held Steady

Connecticut's cannabis tax collections climbed 67% year-over-year in fiscal 2026, even as total sales grew less than 2%, according to state Department of Revenue Services data. The anomaly stems from the state's THC potency tax, which adds a per-milligram charge on all products containing more than 0.5% THC—a threshold that captures nearly every adult-use SKU. Enacted in 2022 alongside the 6.35% sales tax, the potency levy was designed as a public-health deterrent but has functioned as a de facto excise tax on flower and concentrates.

The tax expires October 1, 2026, under legislation passed in May. Operators stocked inventory. Consumers accelerated purchases ahead of the sunset, distorting both revenue and unit-sales trends in the final quarters of the fiscal year.

How the Potency Tax Works

The potency tax charges $0.00625 per milligram of THC in flower and $0.0275 per milligram in concentrates, edibles, and other non-flower products. A typical eighth-ounce of 20% THC flower (roughly 700mg THC) carries a $4.38 potency tax; a 1-gram concentrate cartridge at 85% THC incurs a $23.38 levy. Combined with the 6.35% sales tax, effective tax rates on high-potency products routinely exceeded 25%.

The structure penalizes concentrates and edibles disproportionately. A $40 gram of 90% THC distillate faced a $24.75 potency tax alone—more than 60% of the pre-tax retail price. Operators reported that consumers shifted toward lower-potency flower or made bulk purchases to amortize the per-milligram charge across larger transactions.

Revenue Impact by Product Category

Concentrates and edibles accounted for 58% of total potency-tax collections despite representing 31% of unit sales, state data show. The math is brutal: the per-milligram rate on non-flower products is 4.4 times higher than on flower, creating a structural tilt toward taxing concentrates.

• Flower: $0.00625/mg THC, generated $18.2M in potency tax (42% of total potency revenue)
• Concentrates: $0.0275/mg THC, generated $21.7M (50%)
• Edibles: $0.0275/mg THC, generated $3.5M (8%)

Total potency-tax collections for fiscal 2026 reached $43.4 million, up from $26.1 million the prior year. The 66% year-over-year jump in potency revenue alone explains the 67% overall tax-revenue increase, as sales-tax collections rose just 1.8%.

Operator Margin Pressure

Multi-state operators with Connecticut exposure—including Curaleaf, Trulieve, and Acreage Holdings—absorbed margin compression as they chose not to pass the full potency tax to consumers. Curaleaf's Connecticut stores reported a 340-basis-point decline in gross margin for the quarter ending June 2026, per its earnings call. The company cited "promotional activity to maintain unit velocity in advance of the potency-tax repeal."

Smaller operators faced steeper pressure. Fine Fettle, a Connecticut-based chain with five locations, told analysts it ran negative EBITDA in Q2 2026 after absorbing roughly 60% of the potency tax on concentrates to stay competitive with Massachusetts and Rhode Island pricing. The company's CFO said the tax created a "prisoner's dilemma"—pass it through and lose customers, or eat it and bleed margin.

Consumer Behavior Shifted Ahead of Repeal

Average transaction size jumped 22% in July and August 2026 as consumers front-loaded purchases before the October 1 sunset, state point-of-sale data indicate. Concentrate sales spiked 31% in the two months preceding the repeal, reversing a year-long trend of declining concentrate share. Operators reported customers buying three-month supplies of cartridges and live resin to lock in pre-repeal inventory.

The pull-forward effect will likely depress Q4 2026 sales. Analysts at Viridian Capital Advisors project Connecticut adult-use revenue will decline 12-15% sequentially in October-December as the market normalizes post-repeal.

Legislative Context and What Comes Next

Connecticut's General Assembly voted 98-51 in May 2026 to repeal the potency tax after two years of operator lobbying and evidence that the levy drove cross-border shopping to Massachusetts and Rhode Island. The bill, HB 6801, eliminates the potency tax effective October 1 but leaves the 6.35% sales tax unchanged. Governor Ned Lamont signed the measure June 12, calling the potency tax "well-intentioned but economically counterproductive."

The repeal will cut the effective tax rate on a typical concentrate from 26% to 6.35%, a reduction operators expect will recapture market share from neighboring states. Massachusetts levies a 10.75% excise tax plus local option taxes; Rhode Island charges 20% at retail. Post-repeal, Connecticut's 6.35% rate will be the lowest in New England.

For full background on this story, see the CannIntel topic hub on Connecticut's cannabis market.

The Investor Read

The potency-tax distortion complicates Connecticut comps for the next two quarters, but the October repeal sets up a favorable 2027 revenue trajectory for operators with scale in the state. Curaleaf and Trulieve each operate four Connecticut stores; both companies guided to mid-single-digit same-store sales growth in the state for fiscal 2027, driven by the tax cut and continued store openings.

The bull case: Connecticut becomes a margin-accretive market as operators recapture the 15-20 percentage points of gross margin previously absorbed by the potency tax. The bear case: the pull-forward effect lingers through Q1 2027, and cross-border elasticity proves lower than operators expect—Massachusetts and Rhode Island consumers may not return in volume.

We'll be watching October point-of-sale data closely. If same-store sales decline more than 10% month-over-month, the pull-forward was larger than modeled and 2027 guidance will need a haircut.